Оптимизация терапии бронхиальной астмы с использованием длительно действующего антихолинергического препарата тиотропия бромида

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2012). http://www.ginasthma.org
2. Masoli M et al. The global burden of asthma executive summary of the GINA Dessimenation Committee report. Allergy 2004; 59: 469.
3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Update 2009. www.ginasthma.org
4. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 3-е изд., испр. и доп. М., 2008.
5. Астафьева Н.Г., Гамова И.В., Кобзев Д.Ю. и др. Приверженность к ингаляционной терапии. Рос. аллергол. журн. 2011; 1: 88.
6. www.ginasthma.org
7. Rootmensen GN et al. Predictors of incorrect inhalation technique in patients with Asthma or COPD: A study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv 2010; 23 (5): 323.
8. Humbert M et al. Asthma control or severity: that is the question. Allergy 2007; 62 (2): 95–101.
9. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–12.
10. Yohannes A et al. Ten years of tiotropium: clinical impact and patient perspectives. Int J COPD 2013; 8: 117–25.
11. Ненашева Н.М. Новые возможности достижения контроля астмы с помощью тиотропия бромида. Эффективная фармакотерапия. Пульмонология и оториноларингология. 2014; 2 (29): 2–10.
12. Зыков К.А., Шевелев В.И., Соколов Е.И. Тиотропий у пациентов с хроничекой обструктивной болезнью легких и сочетанной сердечно-сосудистой патологией. Атмосфера. Пульмонология и аллергология. 2013; 2: 2–8.
13. Adams KS, Lowe DK. Tiotropium for adults with inadequately controlled persistent asthma. Ann Pharmacother 2013; 47 (1): 117.
14. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124 (5): 1743–8.
15. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107 (4): 363–70. (Meta-analysis; 1483 patients).
16. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161 (6):1862–8. (Double-blind randomized controlled trial; 180 patients).
17. Disse B et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993; 52: 537–44.
18. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther 2003; 98 (1): 59–69.
19. Martin RJ. Nocturnal Asthma: Mechanisms and Treatment. Ed. by R.J.Martin. New York, 1993; p. 71–115.
20. Catterall JR et al. Is nocturnal asthma caused by changes in airway cholinergic activity? Thorax 1988; 43 (9): 720.
21. Shelley R et al. Meta-analysis: Anticholinergics, but not b-agonists, Reduce Severe Exacerbations and Respiratory Mortality in COPD. Ann Intern Med 2004; 140: 802–13.
22. Donohue JF et al. A 6-monthplacebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
23. Giannini В et al. Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment. Chest 2001; 119: 1671–5.
24. Ohta S, Oda N, Yokoe T et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy 2010; 40 (8): 1266–75.
25. Buels KS, Jacoby DB, Fryer AD. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br J Pharmacol 2012; 165 (5): 1501–14.
26. Архипов В.В. Новые перспективы повышения контроля над бронхиальной астмой. От науки к практике. Практ. пульмонология. 2014; 1: 2–7.
27. Cochrane MG, Bala MV, Downs KE et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
28. Авдеев С.Н. Небулайзерная терапия обструктивных заболеваний легких. Cons. Med. 2011; 13 (3): 36–42.
29. Newman SP, Brown J, Steed KP. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat® Soft MistTM Inhaler with conventional pMDIs with and without spacer devices. Chest 1998; 113: 957–63.
30. Steed KP, Towse LJ, Freund B et al. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered fr om the prototype III hand-held multidose Respimat nebuliser. Eur J Pharm Sci 1997; 5: 55–61.
31. Kerstjens HA, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367 (13): 1198–207.
32. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis 2009; 4: 381–90.
33. Pitcairn G. Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005; 18 (3): 264–72.
34. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft MistTM Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl.) 2011; 4: 145–55.
35. Barczok M et al. Presented at VIII Deutsches Aerosol Therapie Seminar, Marburg, Germany, 2003.
36. Hochrainer D et al. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist InhalerTM and pressurized metered dose inhalers. J Aerosol Med 2005; 18: 273–82.
37. Schürmann W, Schmidtmann S, Moroni P et al. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med 2005; 4 (1): 53–61.
38. Brand P, Hederer B, Austen G et al. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 763–70.
39. Hodder R, Reese PR, Slaton T. Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler. Int J Chron Obstruct Pulmon Dis 2009; 4: 225–32.
40. Freytag F, Rau-Berger H, Glaab T, Wolf K. Respimat® Soft MistTM Inhaler preferred to Diskus by patients with COPD and/or asthma. Am J Respir Crit Care Med 2007; 175: А639.
41. Bateman ED, Kornmann O, Schmidt P et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128 (2): 315–22.
42. Israel E, Drazen JM, Ligget SB et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75–80.
43. Ненашева Н.М. Клинические фенотипы атопической бронхиальной астмы и дифференцированная тактика диагностики и лечения. Дис. … д-р мед. наук; с. 193–9.
44. Bleecker ER, Yancey SW, Baitinger LA et al. Salmeterol response is not affected by beta2- adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118: 809–16.
45. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56 (4): 1054–70.
46. Weiss ST. New approaches to personalized medicine for asthma: Wh ere are we? J Allergy Clin Immunol 2012; 129 (2): 327–34.
47. Chalmers GW, Macleod KJ, Little SA et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (30): 226–30.
48. Soler-Cataluсa JJ, Cosнo B, Izquierdo JL. Consensus Document on the Overlap Phenotype COPD – Asthma in COPD. Arch Bronconeumol 2012; 48 (90): 331–7.
49. Авдеев С.Н. Эффективность и безопасность препарата Спирива® Респимат® при ХОБЛ и бронхиальной астме. Эффективная фармакотерапия. 2014; 18: 10–20.
50. A Multicenter, Randomised, Placebo- and Active-controlled, 5 Way, Crossover Trial to Characterise the Pharmacokinetics and Evaluate the Bronchodilator Efficacy and Safety of Once-daily Tiotropium Delivered (Double-blind) From the Respimat Inhaler as Solution for Inhalation (1,25; 2,5; 5 Mcg or Placebo) and as Inhalation Powder (18 mcg) From the HandiHaler (Open Label) After 4 Week-treatment Periods in Patients With Chronic Obstructive Pulmonary Disease (COPD) NCT0122253. http://clinicaltrials.gov/ct2 /show/study/NCT01222533?sect=X36015

Е.П.Терехова

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва